UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $667,000 Holdings in Alector, Inc. (NASDAQ:ALEC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Alector, Inc. (NASDAQ:ALEC) by 7.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,061 shares of the company’s stock after selling 10,920 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Alector were worth $667,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Acadian Asset Management LLC lifted its holdings in shares of Alector by 32.8% in the 2nd quarter. Acadian Asset Management LLC now owns 590,662 shares of the company’s stock worth $2,681,000 after purchasing an additional 146,015 shares in the last quarter. FMR LLC lifted its position in shares of Alector by 1.0% during the third quarter. FMR LLC now owns 14,595,014 shares of the company’s stock worth $68,013,000 after acquiring an additional 137,794 shares in the last quarter. Panagora Asset Management Inc. grew its position in shares of Alector by 61.7% in the second quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company’s stock valued at $1,613,000 after purchasing an additional 135,614 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Alector by 14.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 760,606 shares of the company’s stock valued at $3,544,000 after buying an additional 94,145 shares during the period. Finally, Deerfield Management Company L.P. Series C increased its holdings in Alector by 7.0% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,148,326 shares of the company’s stock worth $5,213,000 after acquiring an additional 75,481 shares during the period. Institutional investors own 85.83% of the company’s stock.

Insider Buying and Selling at Alector

In other Alector news, insider Sara Kenkare-Mitra sold 26,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $2.52, for a total transaction of $66,780.00. Following the completion of the transaction, the insider now owns 565,215 shares of the company’s stock, valued at $1,424,341.80. This represents a 4.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Marc Grasso sold 16,489 shares of Alector stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total value of $41,552.28. Following the completion of the sale, the chief financial officer now directly owns 330,651 shares in the company, valued at approximately $833,240.52. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 95,161 shares of company stock worth $239,806. Insiders own 9.10% of the company’s stock.

Alector Price Performance

Shares of Alector stock opened at $1.86 on Friday. The firm has a market cap of $182.16 million, a price-to-earnings ratio of -1.09 and a beta of 0.51. Alector, Inc. has a 1 year low of $1.73 and a 1 year high of $8.90. The company has a 50-day moving average of $3.82 and a 200 day moving average of $4.66.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million. On average, equities analysts anticipate that Alector, Inc. will post -1.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALEC. Morgan Stanley downgraded shares of Alector from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $10.00 to $3.00 in a research note on Tuesday, November 26th. BTIG Research decreased their price objective on Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a research note on Tuesday, November 26th. Mizuho cut Alector from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $9.00 to $2.50 in a report on Tuesday. Finally, HC Wainwright reduced their target price on Alector from $35.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Alector presently has an average rating of “Hold” and an average target price of $3.75.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.